海隆控股(01623.HK)發行2022年到期優先票據獲追捧 訂單簿記峰值逾12億美元
海隆控股(01623.HK)發行本金總額2億美元於2022年到期的優先票據,年息為8.25厘。
是次公司新債券發行得到了全球投資者熱烈追捧,獲取共計來自107個投資人賬戶,包括富達基金、施羅德投資、貝萊德資管等諸多高質量的大型國際機構投資人的踴躍認購,訂單簿記峰值超過12億美元,最終交易價格定在8.45%,較初步價格指引大幅收緊超過40個基點。
按地區分佈,99%來自亞洲;1%來自歐洲。按類別來看,認購者91%為基金經理、保險公司;4.5%來自銀行;餘下4.5%來自私人銀行、企業及其他。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.